NCT05952219

Study to Evaluate the Safety and Pharmacokinetics of CKD-379

A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-379 in Healthy Volunteers Under Fed Conditions

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Accepted

Summary

A study to compare the pharmacokinetics and safety between CKD-379 and D759, D745, D029, D150 combination

Detailed description

A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-379 in healthy volunteers under fed conditions

Conditions

• Type II Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	CKD-379	2 tablet administration under fed condition
DRUG	D759+D745+D029+D150	4 tablet co-administration under fed condition

Timeline

• Start date: 2023-06-02
• Primary completion: 2023-06-19
• Completion: 2023-10-30
• First posted: 2023-07-19
• Last updated: 2023-07-19

Locations

1 site across 1 country: South Korea